GlassScriptPhysician profile
Keynalee Ayala
NPI 1720881717
$4,381.59
in general payments reported to CMS, 2019-2025
28 companies · $4,382 in 2025
The $4,382 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,381.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $949.75 | 2025 | Fintepla, Nayzilam, Briviact |
| Axsome Therapeutics, INC. | $415.11 | 2025 | Symbravo |
| Abbvie INC. | $382.89 | 2025 | |
| Pfizer INC. | $275.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $275.51 | 2025 | |
| Eisai INC. | $267.99 | 2025 | |
| Sk Life Science, INC. | $261.41 | 2025 | |
| Neurocrine Biosciences, INC. | $219.48 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $206.97 | 2025 | Austedo Xr |
| Biogen, INC. | $179.25 | 2025 | Leqembi |
| Otsuka America Pharmaceutical, INC. | $175.39 | 2025 | Rexulti |
| Impel Pharmaceuticals LLC | $110.27 | 2025 | Trudhesa |
| Neurelis, INC. | $102.87 | 2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $77.17 | 2025 | Inbrija |
| Acadia Pharmaceuticals INC | $71.70 | 2025 | Daybue |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $61.23 | 2025 | Ultomiris |
| C2n Diagnostics, LLC | $55.68 | 2025 | Precivityad2 |
| Otter Pharmaceuticals, LLC | $55.17 | 2025 | Sympazan |
| Amneal Pharmaceuticals LLC | $51.89 | 2025 | Crexont |
| Lilly USA, LLC | $33.47 | 2025 | Kisunla |
| Livanova USA, INC. | $24.12 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $23.84 | 2025 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $21.06 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.18 | 2025 | Givlaari |
| Amgen INC. | $18.11 | 2025 | Uplizna |
| Supernus Pharmaceuticals, INC. | $16.04 | 2025 | Qelbree |
| Genentech USA, INC. | $15.11 | 2025 | Ocrevus Zunovo |
| Aucta Pharmaceuticals, INC. | $14.94 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keynalee Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.